Armata Pharmaceuticals, Inc. (ARMP) Stock

Armata Pharmaceuticals, Inc. (ARMP) is a Healthcare stock trading at $5.07 (as of 2026-08-21), with a market capitalization of $188.51M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing targeted bacteriophage therapeutics for antibiotic-resistant infections. Its pipeline includes bacteriophage candidates for Staphylococcus aureus bacteremia and Pseudomonas aeruginosa infections, and it also has a partnership with Merck & Co. for developing synthetic bacteriophage candidates.

Understand Armata Pharmaceuticals, Inc.: how it makes money

Armata Pharmaceuticals develops targeted bacteriophage therapeutics for antibiotic-resistant infections, and it currently reports that its revenue comes from grants and awards.

As a clinical-stage biotech, Armata’s near-term profit engine is not product sales, it is externally funded research (grants and awards) that funds trials, while the stock’s direction depends on clinical readouts for its bacteriophage candidates.

Revenue by segment (latest quarter)
Grants$0.0B

Business quality (Solid): Strong early clinical signal metrics are provided for AP-SA02, but the company’s reported revenue is 0.0B and it shows a very large operating loss, so results and funding continuity are central uncertainties.

Bull case

  • Clinical response signal for AP-SA02: Investigator-Assessed Responder Rate at End of Study for AP-SA02 is 100% (per the provided KPI set).
  • Manufacturing scalability metric provided: Manufacturing Capacity is listed as 10000 full courses of phage therapy per year.
  • Strategic partnership: Armata has a partnership agreement with Merck & Co. to develop synthetic bacteriophage candidates for undisclosed infectious disease agents.

Bear case

  • No current revenue and heavy operating losses: For the period shown (2024-06-30), reported revenue is 0.0B and operating margin is -5391.0%, highlighting ongoing financial burn.
  • Dependency on clinical outcomes and study design limits: The Intent-to-Treat Population is 50 subjects, so the company’s key efficacy KPIs are based on a relatively small dataset.
  • Funding risk tied to grants and awards: The only reported segment revenue candidates shown are Grant and Award Revenue and Grant Revenue, both at 0.0B, which underscores reliance on external funding until product revenue exists.
Valuation — source: SEC EDGAR (first-party)
Price$5.07
Market Cap$188.51M
Price / Sales485.86
FCF Yield-14.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$179000.00
Net Margin-38572.6%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMadison Asset Management, LLC ($21.58M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODeborah L. Birx
Employees60
CountryUS
IPO Date1994-05-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Coherus Oncology, Inc. (CHRS)
  • Voyager Therapeutics, Inc. (VYGR)
  • Protalix BioTherapeutics, Inc. (PLX)
  • Caribou Biosciences, Inc. (CRBU)
  • Humacyte, Inc. (HUMA)
  • Invivyd, Inc. (IVVD)
  • LENZ Therapeutics, Inc. (LENZ)
ARMP earnings history · ARMP institutional & insider holders · ARMP KPIs & operating metrics · ARMP financials · ARMP investor presentations & press releases · ARMP SEC filings · ARMP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.